CLC

Across TCGA pan-cancer cohorts, CLC mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CLC data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CLC mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CLC expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

PDAC, GBM, and HNSC are the cancer types where CLC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.537	1.000	.008	12	view →
GBM	OS	Median	All	0.652	0.377	.013	7	view →
HNSC	OS	Quartile	All	0.877	0.626	.023	6	view →
LUAD	DFS	Quartile	All	0.956	0.849	.014	6	view →
CCRCC	DFS	Quartile	All	1.000	0.847	.015	2	view →
LSCC	OS	Median	All	0.910	0.828	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CLC–PDAC (OS)

Open the PDAC breakdown →